Recent chemistry improvements when correctly engineered have demonstrated that most legacy (i.e. generic) drug manufacturing processes are out of date and do not employ best chemistries available. Our relationships with global academic and non-profit institutions like Medicines For All Institute (i.e. joint venture VCU and the Gates Foundation) are investing in this Mission, give us access to enhanced chemical engineering processes of active pharmaceutical ingredient (“API”).
Our technology has been commercially evaluated, validated, tested and deployed. BPP’s continuous flow manufacturing are in use at the Environmental Protection Agency (“EPA”) under a CRADA agreement, at the Bright Path Labs at the EPA in Cincinnati, OH.